Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Crohn's Disease or Ulcerative Colitis
NCT05003947Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Jun 2022
- Primary completion
- Oct 2028
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial in Crohn's disease and ulcerative colitis (UC), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Jun 2022; status: recruiting.
02
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05003947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003947.